Ledipasvir/sofosbuvir for 12 weeks is safe and effective in patients with chronic hepatitis C and hepatitis B coinfection: A phase 3 study in Taiwan

Authors :: Wan-Lung Chuang
Jenny C. Yang
J.-J. Chen
Pei-Jer Chen
Chi-Jen Chu
C. Chen
Gregory Camus
You-Chun Hsu
Tsung-Hui Hu
Rong-Nan Chien
Horng-Yuan Wang
John G. McHutchison
Fangqiu Zhang
Chun-Jen Liu
I-Shyan Sheen
D.M. Brainard
Cheng Yuan Peng
Kuo-Chih Tseng
Benedetta Massetto
Ting-Tsung Chang
Gin-Ho Lo
Source :: Journal of Hepatology. 66:S56-S57
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Hepatology
business.industry
Phases of clinical research
Hepatitis B
medicine.disease
Virology
03 medical and health sciences
0302 clinical medicine
Chronic hepatitis
Coinfection
medicine
LEDIPASVIR/SOFOSBUVIR
030211 gastroenterology & hepatology
In patient
030212 general & internal medicine
business

Full Text Access

Tools